Butler F K, Kotwal R S, Buckenmaier C C, et al. A triple-option analgesia plan for tactical combat casualty care :TCCC guidelines change 13-04[J]. J Spec Oper Med, 2014, 14(1):13-25.
[2]
Blankenstein T N, Gibson L M, Claydon M A, et al. Is intramuscular morphine satisfying frontline medical personnels' requirement for battlefield analgesia in Helmand Province, Afghanistan? A questionnaire study [J]. Br J Pain, 2015, 9(2): 115-121.
[3]
Shackelford S A, Fowler M, Schultz K, et al. Prehospital pain medication use by U.S. Forces in Afghanistan [J]. Mil Med, 2015, 180(3): 304-309.
[4]
Ramirez S, Bebarta V S, Varney S M, et al. Misuse of prescribed pain medication in a military population-a self-reported survey to assess a correlation with age, deployment, combat illnesses, or injury? [J]. Am J Ther, 2017, 24(2): e150-e156.
[5]
NIDA. Substance use and military life drugfacts[EB/OL].[2019-10-1]. https://www.drugabuse.gov/publications/drugfacts/substance-use-military-life.
[6]
Dembek Z F, Chekol T, Wu A. The opioid epidemic: challenge to military medicine and national security [J]. Mil Med, 2020, 185(5-6): e662-e667.
[7]
Jeffery D D, May L, Luckey B, et al. Use and abuse of prescribed opioids, central nervous system depressants, and stimulants among U.S. active duty military personnel in FY 2010 [J]. Mil Med, 2014, 179(10): 1141-1148.
[8]
Ferdinando L. Progress in preventing opioid abuse, more needs to be done[EB/OL].[2018-6-21]. https://www.defense.gov/News/News-Stories/Article/Article/1556690.
[9]
Reed R N, Schurr M J. Acute pain in the trauma patient. [J].Curr Trauma Rep, 2020, 6(4): 147-153.
[10]
Vincent-Lambert C, de Kock J M. Use of morphine sulphate by South African paramedics for prehospital pain management [J]. Pain Res Manag, 2015, 20(3): 141-144.
[11]
Nakar H, Sorkin A, Nadler R, et al. Trends in prehospital pain management: two decades of point-of-injury care [J]. Isr Med Assoc J, 2022, 24(9): 584-590.
Cohen L, Athaide V, Wickham M E, et al. The effect of ketamine on intracranial and cerebral perfusion pressure and health outcomes: a systematic review [J]. Ann Emerg Med, 2015, 65(1): 43-51.e2.
[14]
Wedmore I S, Butler F K Jr. Battlefield analgesia in tactical combat casualty care [J]. Wilderness Environ Med, 2017, 28(2s): S109-S116.
Buckenmaier C C. Requested editorial for: the opioid epidemic: challenge to military medicine and national security [J]. Mil Med, 2020, 185(9-10): e1378-e1379.
[18]
Yudin Y, Rohacs T. The G-protein-biased agents PZM21 and TRV130 are partial agonists of μ-opioid receptor-mediated signalling to ion channels [J]. Br J Pharmacol, 2019, 176(17): 3110-3125.
Hagen N A, Cantin L, Constant J, et al. Tetrodotoxin for moderate to severe cancer-related pain: a multicentre, randomized, double-blind, placebo-controlled, parallel-design trial [J]. Pain Res Manag, 2017, 2017: 7212713.
[21]
Guy G P, Zhang K, Bohm M K, et al. Vital signs: changes in opioid prescribing in the united states,2006-2015[J]. Mmwr Morb Mortal Wkly Rep, 2017, 66(26):697-704.
[22]
Bennett A S, Guarino H, Britton P C, et al. U.S. military veterans and the opioid overdose crisis: a review of risk factors and prevention efforts [J]. Ann Med, 2022, 54(1): 1826-1838.
[23]
Cichowski S B, Rogers R G, Komesu Y, et al. A 10-yr analysis of chronic pelvic pain and chronic opioid therapy in the women veteran population [J]. Mil Med, 2018, 183(11-12): e635-e640.
[24]
Maiocco G, Snider S, Stroupe L M. Veteran-to-veteran program [J]. J Contin Educ Nurs, 2018, 49(11): 493-495.
2023, Vol. 34 
